Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kalypsys Inc.

Latest From Kalypsys Inc.

Deals Of The Week: Merck/Calibr, GSK/Epistem, Biogen Idec/MAKScientific

Shire addresses its Replagal disappointment with the acquisition of FerroKin and its hematology pipeline.

BioPharmaceutical Deals

Merck Ups The Calibr Of Academic-Industry Cooperation

Merck announced March 15 that it plans to invest $90 million over the next seven years in a nonprofit biomedical research center in San Diego dubbed the California Institute for Biomedical Research, or Calibr.

BioPharmaceutical Strategy

New appointments at Aragon Pharmaceuticals

Aragon Pharmaceuticals (US), privately held small-molecule drug discovery company identifying medicines for the treatment of hormonally driven cancers, has appointed Dr Richard Heyman chief executive officer, and has elected Dr Ronald Evans and Dr David Mangelsdorf to its scientific advisory board. Dr Heyman has 20 years' drug discovery experience in the biotech sector, having most recently co-founded Aragon in 2009. Before that, he was chief scientific officer at Kalypsys, where he conducted drug discovery in therapeutic areas including metabolic diseases, pain and inflammation. Dr Evans is professor in the gene expression laboratory and March of Dimes Chair in molecular and developmental biology at the Salk Institute for Biological Studies in La Jolla, California, while Dr Mangelsdorf has been at the University of Texas Southwestern Medical Center in Dallas, where he has been professor and chair of the department of pharmacology, since 1993.

Orthopedics Neurology

Biopharma VCs Move to the Middle in 2006

While the venture capital community spent roughly the same in biopharma investments in 2006 as they did in 2005, they put considerably more money into mid-stage companies (Series B and C investments), and slightly less into Series A and mezzanine rounds, than they had in 2005.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Kalypsys Inc.
  • Senior Management
  • John McKearn, PhD, Pres. & CEO
    Pratik Shah, PhD, CBO
    Paul Grint, MD, Head, Dev. & CMO
  • Contact Info
  • Kalypsys Inc.
    Phone: (858) 754-3300
    10420 Wateridge Cir.
    San Diego, CA 92121